Nosocomial infections are currently considered the major concern for the medical community worldwide. The Centers for Disease Control and Prevention estimated that around 1.7 million hospital-associated infections, contribute to 99,000 deaths each year. Hospital surveys in Europe demonstrated that two thirds of the 25,000 deaths each year caused by Gram negative bacteria. The problem increases with the emergence of antibiotic resistance among the isolated bacterial causes particularly in Gram negative bacteria which can also extend to infect people outside the hospitals.
Ferulic acid is a natural phenolic compound commonly found in many fruits, vegetables, cereals, and coffee. It has been reported that this compound exhibit a wide range of therapeutic effects with applications including anticancer, antidiabetic cardio protective and neuro-protective and anti-inflammatory activities. In addition, studies on the antimicrobial activity of ferulic acid have demonstrated wide spectrum of activity however, with potency less than many available antimicrobial agents.
The objective of this project is to design newly synthetic ferulic acid derivative with chemical modifications that increase the potency, spectrum of activity and stability of the compound to be used as antimicrobial agent for the treatment of infections caused by multi-drug resistant Pseudomonas aeruginosa and other Gram negative bacteria isolated from clinical settings and hospitals.back